Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C28H41N3O3 |
| Molecular Weight | 467.6434 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN(CCC)C(=O)C(CC1=CC=C(OCCN(CC)CC)C=C1)NC(=O)C2=CC=CC=C2
InChI
InChIKey=FDBWMYOFXWMGEY-UHFFFAOYSA-N
InChI=1S/C28H41N3O3/c1-5-18-31(19-6-2)28(33)26(29-27(32)24-12-10-9-11-13-24)22-23-14-16-25(17-15-23)34-21-20-30(7-3)8-4/h9-17,26H,5-8,18-22H2,1-4H3,(H,29,32)
Tiropramide is an antispasmodic medication. It acts by increasing cAMP concentration in smooth muscle possibly because of inhibition of cAMP catabolism. The drug is marketed worldwide for the treatment of irritable bowel syndrome, biliary dyskinesia, acute spasmodic dysphoric syndromes, and other urological and gynecological disorders.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006939 |
19.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ALFOSPAS Approved UsePainful-spastic syndromes such as acute hepatobiliary colic, abdominal different nature, kidney or ureteral. Spasms and abdominal pain originating from gastrointestinal dyskinesia, cholelithiasis, cholecystitis, post-surgical adhesions. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
106.76 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17127027/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIROPRAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
352.81 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17127027/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIROPRAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.07 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17127027/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIROPRAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
300 mg 3 times / day multiple, oral Highest studied dose Dose: 300 mg, 3 times / day Route: oral Route: multiple Dose: 300 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
400 mg single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA03AC05
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
||
|
WHO-ATC |
A03AC05
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
||
|
NCI_THESAURUS |
C29698
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m10892
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB11119MIG
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | |||
|
2681
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | |||
|
C152660
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | |||
|
55837-29-1
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | |||
|
100000092517
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | |||
|
3805
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | |||
|
R7S0904CN2
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | |||
|
DTXSID70866514
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | |||
|
38315
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | RxNorm | ||
|
DB13091
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104688
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | |||
|
TIROPRAMIDE
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | |||
|
C031173
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY | |||
|
42262
Created by
admin on Mon Mar 31 18:48:17 GMT 2025 , Edited by admin on Mon Mar 31 18:48:17 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
